Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125

Research output: Contribution to journalArticle

Standard

Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. / Van Calster, Ben; Timmerman, Dirk; Bourne, Tom; Testa, Antonia Carla; Van Holsbeke, Caroline; Domali, Ekaterini; Jurkovic, Davor; Neven, Patrick; Van Huffel, Sabine; Valentin, Lil.

In: Journal of the National Cancer Institute, Vol. 99, No. 22, 2007, p. 1706-1714.

Research output: Contribution to journalArticle

Harvard

Van Calster, B, Timmerman, D, Bourne, T, Testa, AC, Van Holsbeke, C, Domali, E, Jurkovic, D, Neven, P, Van Huffel, S & Valentin, L 2007, 'Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125', Journal of the National Cancer Institute, vol. 99, no. 22, pp. 1706-1714. https://doi.org/10.1093/jnci/djm199

APA

Van Calster, B., Timmerman, D., Bourne, T., Testa, A. C., Van Holsbeke, C., Domali, E., Jurkovic, D., Neven, P., Van Huffel, S., & Valentin, L. (2007). Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. Journal of the National Cancer Institute, 99(22), 1706-1714. https://doi.org/10.1093/jnci/djm199

CBE

Van Calster B, Timmerman D, Bourne T, Testa AC, Van Holsbeke C, Domali E, Jurkovic D, Neven P, Van Huffel S, Valentin L. 2007. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. Journal of the National Cancer Institute. 99(22):1706-1714. https://doi.org/10.1093/jnci/djm199

MLA

Vancouver

Author

Van Calster, Ben ; Timmerman, Dirk ; Bourne, Tom ; Testa, Antonia Carla ; Van Holsbeke, Caroline ; Domali, Ekaterini ; Jurkovic, Davor ; Neven, Patrick ; Van Huffel, Sabine ; Valentin, Lil. / Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. In: Journal of the National Cancer Institute. 2007 ; Vol. 99, No. 22. pp. 1706-1714.

RIS

TY - JOUR

T1 - Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125

AU - Van Calster, Ben

AU - Timmerman, Dirk

AU - Bourne, Tom

AU - Testa, Antonia Carla

AU - Van Holsbeke, Caroline

AU - Domali, Ekaterini

AU - Jurkovic, Davor

AU - Neven, Patrick

AU - Van Huffel, Sabine

AU - Valentin, Lil

PY - 2007

Y1 - 2007

N2 - Background Subjective evaluation of gray-scale and Doppler ultrasound findings (i. e., pattern recognition) by an experienced examiner and preoperative serum levels of CA-125 can both discriminate benign from malignant adnexal ( i. e., ovarian, paraovarian, or tubal) masses. We compared the diagnostic performance of these methods in a large multicenter study. Methods In a prospective multicenter study-the International Ovarian Tumor Analysis-1066 women with a persistent adnexal mass underwent transvaginal gray-scale and color Doppler ultrasound examinations by an experienced examiner within 120 days of surgery. Pattern recognition was used to classify a mass as benign or malignant. Of these women, 809 also had blood collected preoperatively for measurement of serum CA-125. Various levels of CA-125 were used as cutoffs to classify masses. Results from both assays were then compared with histologic findings after surgery. Results Pattern recognition correctly classified 93% (95% confidence interval [CI]=90.9% to 94.6%) of the tumors as benign or malignant. Serum CA-125 correctly classified at best 83% ( 95% CI=80.3% to 85.6%) of the masses. Histologic diagnoses that were most often misclassified by CA-125 were fibroma, endometrioma, and abscess ( false-positive results) and borderline tumor ( false-negative results). Pattern recognition correctly classified 86% ( 95% CI=81.1% to 90.4%) of masses of these four histologic types as being benign or malignant, whereas a serum CA-125 at a cutoff of 30 U/mL correctly classified 41% ( 95% CI=34.4% to 47.5%) of them. Pattern recognition assigned a correct specific histologic diagnosis to 333 (59%, 95% CI=54.5% to 62.8%) of the 567 benign lesions. Conclusion Pattern recognition was superior to serum CA-125 for discrimination between benign and malignant adnexal masses.

AB - Background Subjective evaluation of gray-scale and Doppler ultrasound findings (i. e., pattern recognition) by an experienced examiner and preoperative serum levels of CA-125 can both discriminate benign from malignant adnexal ( i. e., ovarian, paraovarian, or tubal) masses. We compared the diagnostic performance of these methods in a large multicenter study. Methods In a prospective multicenter study-the International Ovarian Tumor Analysis-1066 women with a persistent adnexal mass underwent transvaginal gray-scale and color Doppler ultrasound examinations by an experienced examiner within 120 days of surgery. Pattern recognition was used to classify a mass as benign or malignant. Of these women, 809 also had blood collected preoperatively for measurement of serum CA-125. Various levels of CA-125 were used as cutoffs to classify masses. Results from both assays were then compared with histologic findings after surgery. Results Pattern recognition correctly classified 93% (95% confidence interval [CI]=90.9% to 94.6%) of the tumors as benign or malignant. Serum CA-125 correctly classified at best 83% ( 95% CI=80.3% to 85.6%) of the masses. Histologic diagnoses that were most often misclassified by CA-125 were fibroma, endometrioma, and abscess ( false-positive results) and borderline tumor ( false-negative results). Pattern recognition correctly classified 86% ( 95% CI=81.1% to 90.4%) of masses of these four histologic types as being benign or malignant, whereas a serum CA-125 at a cutoff of 30 U/mL correctly classified 41% ( 95% CI=34.4% to 47.5%) of them. Pattern recognition assigned a correct specific histologic diagnosis to 333 (59%, 95% CI=54.5% to 62.8%) of the 567 benign lesions. Conclusion Pattern recognition was superior to serum CA-125 for discrimination between benign and malignant adnexal masses.

U2 - 10.1093/jnci/djm199

DO - 10.1093/jnci/djm199

M3 - Article

C2 - 18000221

VL - 99

SP - 1706

EP - 1714

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 1460-2105

IS - 22

ER -